Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01611974 · ClinicalTrials.gov registry record · Phase 2
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01611974 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 120 participants.
The verdict
NCT01611974, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.
Interventions
- DRUG Maribavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-07-17 |
| Est. Completion | 2014-12-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01611974
The ClinicalTrials.gov registry entry for NCT01611974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maribavir is the first listed.
NCT01611974 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01611974 about?
NCT01611974 is a clinical study titled "Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients". This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or soli...
What is the current status of trial NCT01611974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2012-07-17. Estimated completion is 2014-12-05.
What interventions are being tested in trial NCT01611974?
The interventions under investigation include: Maribavir (DRUG).
Who is sponsoring clinical trial NCT01611974?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.